文献速递治疗药物监测与药物基因组学肝肾功能剂量调整

稳定期成人肝移植受者口服缓释他克莫司(Envarsus)的群体药代动力学与遗传学研究

Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients.
PubMed 文献 · Br J Clin Pharmacol · 2021-05-04

结果显示二房室模型拟合最佳,未发现显著降低个体间变异的协变量,3点有限采样策略(0、4、8小时)可较好预测AUC,CYP3A状态对初始剂量优化似乎无用。

要点

  • Envarsus在肝移植受者中可用二房室模型描述,清除率为3.27 L/h。
  • CYP3A4/5、IL-6/-10/-18基因型未显著降低个体间变异。
  • 3点有限采样策略(0、4、8小时)可较好预测AUC,中位偏差1.8%。

核心结论

  • 3点有限采样策略可充分预测Envarsus的AUC。
  • 未发现包括CYP3A状态在内的临床相关协变量影响Envarsus药代动力学,对初始剂量优化似乎无用。

研究设计与样本

  • 成人肝移植受者从缓释他克莫司(Advagraf)转换为Envarsus,采用全血和干血斑采样。
  • 考察人口学因素及受者与供者CYP3A4、CYP3A5、IL-6、IL-10、IL-18基因型作为潜在协变量。

主要发现

  • 带延迟吸收的二房室模型最适合描述群体药代动力学参数。
  • 群体药代动力学参数:清除率3.27 L/h,房室间清除率9.6 L/h,中央室和周边室分布容积分别为95 L和500 L。
  • 未发现显著降低个体间变异的协变量。
  • 最佳3点有限采样策略为t=0、4、8小时,中位偏差1.8%(-12.5-12.5)。

关键数值与推荐

  • 3点有限采样策略时间点为0、4、8小时,中位偏差1.8%(-12.5-12.5)。

临床怎么用

  • 临床可考虑采用0、4、8小时三点有限采样策略估计Envarsus的AUC。
  • 转换至Envarsus时,CYP3A基因型检测对初始剂量优化的价值似乎有限。

局限性

  • 研究仅纳入稳定期成人肝移植受者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Meltdose tacrolimus (Envarsus) is marketed as a formulation with a more consistent exposure. Due to the narrow therapeutic window, therapeutic drug monitoring is essential to maintain adequate exposure. The primary objective of this study was to develop a population pharmacokinetic (PK) model of Envarsus among liver transplant patients and select a limited sampling strategy (LSS) for AUC estimation. The secondary objective was to investigate potential covariates including CYP3A/IL genotype suitable for initial dose optimization when converting to Envarsus. METHODS: Adult liver transplant patients were converted from prolonged release tacrolimus (Advagraf) to Envarsus and blood samples were obtained using whole blood and dried blood spot sampling. Subsequently the population PK parameters were estimated using nonlinear-mixed effect modelling. Demographic factors, and recipient and donor CYP3A4, CYP3A5, IL-6, -10 and -18 genotype were tested as potential covariates to explain interindividual variability. RESULTS: Fifty-five patients were included. A 2-compartment model with delayed absorption was the most suitable to describe population PK parameters. The population PK parameters were as follows: clearance, 3.27 L/h; intercompartmental clearance, 9.6 L/h; volume of distribution of compartments 1 and 2, 95 and 500 L, respectively. No covariates were found to significantly decrease interindividual variability. The best 3-point LSS was t = 0,4,8 with a median bias of 1.8% (-12.5-12.5). CONCLUSIONS: The LSS can be used to adequately predict the AUC. No clinically relevant covariates known to influence the PK of Envarsus, including CYP3A status, were identified and therefore do not seem useful for initial dose optimization.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Martial LC, Biewenga M, Ruijter BN, et al. Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. Br J Clin Pharmacol. 2021. PMID: 33786892. doi:10.1111/bcp.14842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。